Published online before print November 3, 2003, doi: 10.1161/01.HYP.0000101690.58391.13
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:1100.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking
The Framingham Heart Study
From the Framingham Heart Study (J.S., D.L., P.W.F.W., R.S.V.), Framingham, Mass; the Department of Preventive Medicine (D.L., R.S.V.), Cardiology Section (R.S.V.), and Endocrinology Division (P.W.F.W.), Boston University School of Medicine, Boston, Mass; the Department of Mathematics (L.S., R.B.D.), Boston University, Boston, Mass; the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging (P.F.J., J.S., I.H.R.), Tufts University, Boston, Mass; and the National Heart, Lung, and Blood Institute (NHLBI; D.L.), Bethesda, Md.
Correspondence to Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mt Wayte Ave, Framingham, MA 01702-5803. E-mail vasan{at}fram.nhlbi.nih.gov
Plasma homocysteine is cross-sectionally associated with blood pressure in large, community-based studies. It is unknown whether elevated plasma homocysteine predicts hypertension incidence. We investigated the relations of baseline plasma total homocysteine levels to hypertension incidence and blood pressure tracking in 2104 Framingham Heart Study participants (mean age, 57 years; 58% women), who were free of hypertension, myocardial infarction, heart failure, atrial fibrillation, or renal failure at baseline. Baseline mean±SD plasma homocysteine was 10.1±3.7 µmol/L. On follow-up 4 years from baseline, 360 persons (17.1%) had developed hypertension, and 878 persons (41.7%) had progressed to a higher blood pressure stage. In unadjusted analyses, a 1-SD higher log homocysteine value was associated with increased odds of developing hypertension (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.05 to 1.32) and increased odds of blood pressure progression (OR, 1.17; 95% CI, 1.07 to 1.27). The relations of plasma homocysteine to the incidence of hypertension or blood pressure progression were statistically nonsignificant in age- and sex-adjusted logistic regression models (OR, 0.98; 95% CI, 0.87 to 1.11 and OR, 1.05; 95% CI, 0.96 to 1.16, respectively) and in multivariable models adjusted for age, sex, body mass index, diabetes, interim weight change, smoking, serum creatinine, baseline blood pressure, and blood pressure category (OR, 0.92; 95% CI, 0.81 to 1.06 and OR, 1.07; 95% CI, 0.97 to 1.18, respectively). In conclusion, we found no major relation of baseline plasma homocysteine levels to hypertension incidence or longitudinal blood pressure progression in a large, community-based cohort of nonhypertensive individuals after adjustment for age, sex, and other important covariates.
Key Words: hypertension, detection and control • blood pressure • homocysteine • metabolism • epidemiology • longitudinal studies
This article has been cited by other articles:
 |
|
 |
|
  J. P. Forman, H. Choi, and G. C. Curhan Uric Acid and Insulin Sensitivity and Risk of Incident Hypertension Arch Intern Med, January 26, 2009; 169(2): 155 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, and T. Murohara Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation Europace, August 1, 2008; 10(8): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Levy, S.-J. Hwang, A. Kayalar, E. J. Benjamin, R. S. Vasan, H. Parise, M. G. Larson, T. J. Wang, J. Selhub, P. F. Jacques, et al. Associations of Plasma Natriuretic Peptide, Adrenomedullin, and Homocysteine Levels With Alterations in Arterial Stiffness: The Framingham Heart Study Circulation, June 19, 2007; 115(24): 3079 - 3085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. McMahon, C. M. Skeaff, S. M. Williams, and T. J. Green Lowering Homocysteine with B Vitamins Has No Effect on Blood Pressure in Older Adults J. Nutr., May 1, 2007; 137(5): 1183 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wang, P. Gona, M. G. Larson, D. Levy, E. J. Benjamin, G. H. Tofler, P. F. Jacques, J. B. Meigs, N. Rifai, J. Selhub, et al. Multiple Biomarkers and the Risk of Incident Hypertension Hypertension, March 1, 2007; 49(3): 432 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Joseph, R. H. Kennedy, S. Devi, J. Wang, L. Joseph, and M. Hauer-Jensen Protective role of mast cells in homocysteine-induced cardiac remodeling Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2541 - H2545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Becker, A. Adler, A. Schneeberger, H. Huang, Z. Wang, E. Walsh, A. Koller, and T. H. Hintze Hyperhomocysteinemia, a Cardiac Metabolic Disease: Role of Nitric Oxide and the p22phox Subunit of NADPH Oxidase Circulation, April 26, 2005; 111(16): 2112 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Sobol, E. Bald, and J. Loba Fractions of Total Plasma Homocysteine in Patients with Ischemic Stroke Before the Age of 55 Years Angiology, March 1, 2005; 56(2): 201 - 209. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Forman, E. B. Rimm, M. J. Stampfer, and G. C. Curhan Folate Intake and the Risk of Incident Hypertension Among US Women JAMA, January 19, 2005; 293(3): 320 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chrysohoou, D. B Panagiotakos, C. Pitsavos, A. Zeimbekis, A. Zampelas, L. Papademetriou, C. Masoura, and C. Stefanadis The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease-free people: the 'ATTICA' study Vascular Medicine, May 1, 2004; 9(2): 117 - 123. [Abstract] [PDF]
|
|